Skip to main content
Clinical Trials/NL-OMON49172
NL-OMON49172
Completed
Phase 2

A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults - PARC

Cancer Research UK Clinical Trials Unit0 sites4 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
onbehandelbare en/of terugkerende vorm van kanker: leukemie, hoogradig glioom, neuroblastoom, sarcoom
Sponsor
Cancer Research UK Clinical Trials Unit
Enrollment
4
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial is onging in other countries

Registry
who.int
Start Date
TBD
End Date
January 18, 2022
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Cancer Research UK Clinical Trials Unit

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria
  • \* Aged 1\- \<25 years old at the time of study registration
  • \* Histologically confirmed disease in one of the following four groups:
  • o Group 1 \- Acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia
  • o Group 2 \- Neuroblastoma
  • o Group 3 \- Sarcoma
  • o Group 4 \- High grade glioma (as defined by 2016 WHO CNS classification)
  • \* Radiological or laboratory evidence of disease progression (during or after
  • completion of first line treatment) or any subsequent recurrence (biopsy at
  • relapse is not mandated).

Exclusion Criteria

  • Previous treatment with another therapeutic arginine depleting drug (bacterial
  • or human) or arginase inhibitor
  • \* Presence of any \>\= CTCAE grade 3 clinically significant treatment\-related
  • toxicity from prior therapies
  • \* Pregnant or lactating female
  • \* Evidence of uncontrolled infection

Outcomes

Primary Outcomes

Not specified

Similar Trials